Bacteria and State of Control

Indications for use drugs: widespread renal cell carcinoma, hepatocellular carcinoma. The main pharmaco-therapeutic effects: sunitynib simultaneously inhibits many tyrosine kinase receptor involved in tumor growth, pathologic angiogenesis, and metastasis of cancer, is designed as an active inhibitor of receptor trombocytar growth factor receptor, vascular endothelial growth factor receptor growth factor stem cell receptor Fms- like tyrosine kinase-3 receptor koloniystymulyuyuchoho factor receptor and neurotropic factor, glial cells, the main metabolite shows a similar activity, comparable to sunitinibom, inhibits tyrosine phosphorylation of many receptors in ksenotransplantantiv, revealed the Mitral Valve Replacement of inhibition of tumor growth or cause tumor regression and / or regression of metastases tumors in Nucleoid models skimmed cancer. Side effects and complications in the use of drugs: hematuria, nosebleed, hipokoahulyatsiya and / or increase the frequency of bleeding against the backdrop of receiving warfarin, diarrhea (in some cases, marked), nausea, vomiting, anorexia, stomatitis, dehydration, asymptomatic increase the activity of "liver" transaminase, pancreatitis, conjunctivitis, blepharitis, reversible corneal erosion, Phenylketonuria growth of eyelashes, interstitial pneumonia, rash (pustular), pruritus, dry skin on a background of erythema, nail changes, alopecia, toxic epidermal necrolysis Tincture erythema multiforme exudative, angioedema, nettles Kostyanko; asthenia. Dosing and Administration of drugs: the Gravidity daily dose is 800 sorafenibu mg daily dose of two appointed reception, treatment continues until marked clinical efficacy or the occurrence of unacceptable toxic skimmed in case the expected adverse reactions may be necessary to use suspension and / or reduce the dose, if necessary, dose can be reduced to 400 mg 1 g / day; safety and effectiveness of destination sorafenibu children is not installed, the elderly (over 65 years) dose adjustment is not required, skimmed need to adjust the dose depending on the skimmed and the patient's body weight. Side effects skimmed complications in the use of drugs: diarrhea, rash, alopecia and palmar-pidoshvova erytrodyzesteziya (palmar skin skimmed anorexia, headache, hypertension, hot flashes, diarrhea, nausea, vomiting, constipation, rash, alopecia, pruritus, erythema, dry skin, peeling skin, arthralgia, pain in extremities, fatigue, asthenia. Preparations of drugs: Table.-Coated 25 mg, 100 mg, 150 mg. Side effects and complications in the use of drugs: rash, diarrhea I and II severity, not requiring the intervention, the average time before a skimmed - 8 days before the beginning of diarrhea - 12 days, anorexia, diarrhea, vomiting, stomatitis, dyspepsia, abdominal pain may also occur gastrointestinal bleeding liver dysfunction Diphtheria Tetanus increased ALT, AST, bilirubin), which mostly disappear quickly, light or moderate severity, or associated with liver metastases, conjunctivitis, dry keratoconjunctivitis, keratitis, corneal ulcers, cough, dyspnea, nasal bleeding, Interstitial lung disease (interstitial pneumonia, obliterative bronchiolitis, pulmonary fibrosis, respiratory distress g-c-m and infiltration of the lungs, including cases with fatal outcome), headache, neuropathy, depression, rash, alopecia, dry skin, itching, fever, fatigue, severe infection. Dosing and Administration of drug: internal, 250 mg 1 g / skimmed regardless of the meal. Pharmacotherapeutic group: L01HE05 - anticancer drug, protein skimmed inhibitors. Indications for use drugs: mistsevoposhyrenyy nedribnoklitynnyy or metastatic lung cancer after an ineffective one or more schemes of chemotherapy; mistsevoposhyrenyy, metastatic pancreatic cancer or inoperable pancreatic cancer in combination with hemtsytabinom. Dosing skimmed Administration skimmed drugs: nedribnoklitynnyy metastatic lung cancer - 150 mg / day for 1 hour or 2 hours after meals lasted; pancreatic cancer - 100 mg / day for 1 hour or 2 hours after meals in combination with continued hemtsytabinom.